Videos

Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.

Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...

Gordon Kuntz sits down with Bo Gamble of the Community Oncology Alliance to discuss the ASCO-COA Oncology Medical Home Model, which established core elements needed to deliver equitable, high-quality cancer care.

Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.

Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.

Katherine Chaves, MD, discusses a study that evaluated adherence to both preoperative glucose testing and USPSTF DM screening guidelines, and aimed to identify the prevalence of impaired glucose metabolism in unscreened patients with...

Katharine Esselen, MD, MBA, discusses a study she worked on that explores the factors that may predispose patients receiving radiation treatment for gynecologic cancer to experience increased financial toxicity.

David Barrington, MD, discusses a study that sought to describe national treatment patterns over time and examine associations between treatment modality and overall survival in patients with endometrioid endometrial carcinoma.

Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.

John Burke, MD, analyzes the safety and efficacy of umbralisib alone and in combination with ublituximab (U2), and U2 plus bendamustine in patients with relapsed/refractory DLBCL.